Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer
JAMA Network Open · 20.03.2025 · 8 (3) · e251186
DOI: 10.1001/jamanetworkopen.2025.1186 ↗Kurz gefasst
Fachartikel in der Zeitschrift JAMA Network Open, online erschienen am 20.03.2025. Verfasst von Shahla Bari und 9 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Oncology, Duke Cancer Institute, Durham, North Carolina. Hauptthemen laut MEDLINE: Practice Patterns, Physicians', Colorectal Neoplasms, Immunotherapy, Immune Checkpoint Inhibitors. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 35 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Abstract (Originalsprache)
Importance Immune checkpoint inhibitors (ICIs) have been approved for treatment of microsatellite instable (MSI-H) metastatic colorectal cancer (mCRC), but factors associated with receipt and efficacy of ICIs in routine clinical practice remain largely unknown.
Objective
To identify factors associated with receipt of ICIs and associated survival outcomes among patients with mCRC in routine clinical practice. Design, Setting, and Participants This population-based cohort study used deidentified data from a nationwide electronic health record–derived database to include 18 932 patients diagnosed with mCRC between January 2013 and June 2019. Population-based patients were diagnosed with de novo mCRC and had at least 2 documented clinical visits on or after the date of diagnosis. The study analyses were performed between September 2020 and April 2021. Exposure Patients received ICI therapy and/or chemotherapy as part of a systemic treatment for mCRC. Main Outcomes and Measures The outcomes were receipt of ICI therapy, overall survival (OS), and time to treatment discontinuation (TTD).
Results
In this cohort study of 18 932 patients diagnosed with mCRC (10 537 [55.7%] male; 546 [2.9%] Asian, 2005 [10.6%] Black or African American, 1674 [8.8%] Hispanic, 12 338 [65.2%] White, 4043 [21.4%] unknown race or ethnicity; median [IQR] age at metastatic diagnosis, 64.6 [55.0-73.3] years), patients with MSI-H tumors had a significantly higher probability of receiving ICIs than those with microsatellite stable (MSS) tumors (odds ratio [OR], 22.66 [95% CI, 17.30-29.73]; P < .001), whereas patients initially diagnosed with synchronous mCRC had significantly lower odds of receiving ICIs than patients with metachronous mCRC (OR, 0.57 [95% CI, 0.45-0.73]; P < .001). Patients with MSI-H tumors who received ICIs as first line of therapy had significantly longer OS than those receiving chemotherapy only (HR, 0.37 [95% CI, 0.25-0.56]; P < .001). Among patients with MSS tumors, ICI-based therapy was associated with significantly longer OS for patients with high albumin level (vs low: HR, 0.28 [95% CI, 0.18-0.45]; P < .001) and antibiotic use (vs nonuse: HR, 0.43 [95% CI, 0.27-0.67]; P < .001), but a significantly shorter OS for patients with synchronous mCRC (vs metachronous: HR, 1.90 [95% CI, 1.24-2.89]; P = .003). In addition, 29 out of 235 patients with MSS tumors (12.3%) experienced durable responses on ICI-based therapy. Similar patterns of associations with TTD were observed. Conclusions and Relevance In this cohort study of patients with mCRC, clinical characteristics were associated with different survival outcomes in patients treated with ICI-based therapy, with important clinical implications for patients with MSS tumors who are generally unresponsive to immunotherapy.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Substanzen
Autor:innen und Institutionen
- Department of Medical Oncology, Duke Cancer Institute, Durham, North Carolina.
- Department of Biostatistics and Bioinformatics, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
- Department of Gastrointestinal Oncology, H. Lee Moffitt Cancer Center and Research Institute, Tampa, Florida.
- Department of Oncology, Mayo Clinic, Rochester, Minnesota.
- University of Pittsburgh School of Medicine, Pennsylvania.
- Department of Surgery, University of Maryland School of Medicine, Baltimore.
Zitieren
APA
Bari, S., Matejcic, M., Kim, R. D., Xie, H., Sahin, I. H., Powers, B. D., Teer, J. K., Chan, T. A., Felder, S. I., & Schmit, S. L. (2025). Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer. JAMA Network Open, 8(3), e251186. https://doi.org/10.1001/jamanetworkopen.2025.1186
Vancouver
Bari S, Matejcic M, Kim RD, Xie H, Sahin IH, Powers BD, et al. Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer. JAMA Network Open. 2025;8(3):e251186. doi:10.1001/jamanetworkopen.2025.1186
BibTeX
@article{Bari2025,
author = {Bari, Shahla and Matejcic, Marco and Kim, Richard D and Xie, Hao and Sahin, Ibrahim H and Powers, Benjamin D and Teer, Jamie K and Chan, Timothy A and Felder, Seth I and Schmit, Stephanie L},
title = {Practice Patterns and Survival Outcomes of Immunotherapy for Metastatic Colorectal Cancer},
journal = {JAMA Network Open},
year = {2025},
volume = {8},
number = {3},
pages = {e251186},
doi = {10.1001/jamanetworkopen.2025.1186}
}
EUVIMED